Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496469 · ClinicalTrials.gov registry record · Phase 2
Effect of Febuxostat on Blood Pressure
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT01496469 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 121 participants.
The verdict
NCT01496469, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).
Interventions
- DRUG Placebo
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496469
The ClinicalTrials.gov registry entry for NCT01496469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01496469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496469 about?
NCT01496469 is a clinical study titled "Effect of Febuxostat on Blood Pressure". The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).
What is the current status of trial NCT01496469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2012-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01496469?
The interventions under investigation include: Placebo (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01496469?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.